Eli Lilly and Company (NYSE:LLY) said that its new oral medication Foundayo (orforglipron) is now available in the United States for adults with obesity or those who are overweight and have related health conditions, following FDA approval granted on April 1, 2026. The treatment is taken once daily and does not require restrictions related to food or water.
The medication will start at $149 per month for self-pay patients at the lowest dosage level. Commercially insured patients who qualify for the Foundayo savings card may pay as little as $25 per month. For individuals enrolled in Medicare Part D, access to the drug is expected to begin July 1, 2026, at a monthly cost of $50.
Foundayo can be obtained through LillyDirect and telehealth platforms, with distribution expected to expand to retail pharmacies across the U.S.
In clinical studies, participants taking the highest dose and remaining on therapy lost an average of 27.3 pounds, compared with 2.2 pounds among those receiving a placebo.
The ATTAIN clinical development program included more than 4,500 participants across two global registration trials. The ATTAIN-1 study enrolled 3,127 participants from multiple countries, while ATTAIN-2 involved more than 1,600 individuals with obesity or overweight and type 2 diabetes.
Foundayo includes warnings regarding the risk of thyroid tumors, including thyroid cancer. Frequently reported side effects include nausea, constipation, diarrhea, vomiting, indigestion, stomach pain, headache, abdominal swelling, fatigue, belching, heartburn, gas, and hair loss.
The drug should not be used together with other GLP-1 receptor agonist treatments. Orforglipron was originally discovered by Chugai Pharmaceutical Co., Ltd. and later licensed to Lilly in 2018.